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Introduction 
 
Acetaminophen is commonly used as a postoperative analgesic for patients who 
undergo surgery. According to the manufacturer’s information accompanying the 
intravenous (i.v.) acetaminophen (Acelio®; Terumo Corp., Japan), the maximal dose for 
adults is 1 g of Acelio®, and for patients with body weight <50 kg, the maximal dose 
should be 15 mg/kg. However, because the mean weights of adult Japanese men and 
women are 65.8 ± 11 and 53.2 ± 9.3 kg, respectively, based on Japanese government 
statistics for 2014 [1], many Japanese patients should receive the uniform dose of 1 g. 
 In general, the amount of anesthetics administered in single dose is calculated on the 
basis of body size scalars, such as weight, in accordance with the pharmacokinetic (PK) 
characteristics of the drug. When designing a dosing regimen for i.v. acetaminophen, it 
is reasonable to base this on a body size scalar to avoid potential underdosing or 
overdosing and to use computer simulation of plasma or effect site drug concentrations 
with appropriate PK models of acetaminophen so that drug concentrations will achieve 
the therapeutic range. 
 For this purpose, PK models with compartmental model structures are required 
because usual PK simulation programs used mainly by anesthesiologists, such as  
Tivatrainer® (http://www.eurosiva.eu/tivatrainer/TTweb/ TTinfo.html; last accessed on 
July 22, 2016) or STANPUMP (http://opentci.org/code/stanpump; last accessed on July 
22, 2016), predict the time course of plasma drug concentrations using compartmental 
PK parameter estimates (such as for the volume of distribution, clearance, or rate 
constant), rather than the results of non-compartmental analysis. As yet, there have been 
no reports of a compartmental PK model for i.v. acetaminophen in Japanese adults. In 
non-Japanese patients, some PK models of i.v. acetaminophen for adolescent [2] or 
adult [3, 4] perioperative patients have been reported, with various factors that influence 
PK parameter estimates, including age [3, 4], creatinine clearance [3], and body size [4]. 
Although the results of non-compartmental PK analysis suggest that acetaminophen 
administration is not prone to intrinsic ethnic differences between Japanese and 
non-Japanese [5], whether the PK models with compartmental structures mentioned 
above also predict the correct plasma drug concentrations in Japanese patients is still 
unknown. 
 The aim of this study was therefore to evaluate the predictive performances of three 
published PK models [2, 3, 6] for i.v. acetaminophen and to build a compartmental 
population PK model for i.v. acetaminophen in Japanese patients who undergo surgery 
under general anesthesia. 
 
Methods 
 
This study was approved by Fukushima Medical University Ethics committee 
(approval number: 1941) and was registered at UMIN-CTR (UMIN0000 13418). The 
study design was a single-dose PK study using multiple study groups and sampling 
intervals and a population PK study.  
Twelve patients aged 18–75 years who were scheduled to undergo elective surgery 
and who would receive i.v. acetaminophen for postoperative analgesia were enrolled. 
Their physical status was American Society of Anesthesiologists classification I–II. All 
patients provided written informed consent. Exclusion criteria included a known allergy 
to acetaminophen; psychoneurotic disorders; psychiatric pharmacotherapy; chronic use 
of acetaminophen, NSAIDs or opioids; women who were pregnant or breast-feeding; 
anemia (hemoglobin <8 g/dL); liver or advanced renal dysfunction; and those who were 
considered inadequate. The patients were randomly allocated to three groups according 
to the duration of acetaminophen infusion (1) the ‘short’ group (1 g of acetaminophen 
infused over 15 min), (2) the ‘medium’ group (1 g of acetaminophen infused over 60 
min), and (3) the ‘long’ group (1 g of acetaminophen infused over 120 min). This 
allocation was intended to facilitate the observation of the time course of plasma 
acetaminophen concentrations at different infusion speeds. The patients did not receive 
premedication. In the operating room, standard monitoring was performed, including 
electrocardiography, noninvasive blood pressure monitoring, pulse oximetry, 
capnometry, and body temperature measurements. General anesthesia was induced and 
maintained at the attending anesthesiologist’s discretion. During surgery, 1 g of i.v. 
acetaminophen was infused over the selected duration (15, 60, or 120 min) using two 
infusion pumps (TE-SS702 N®; Terumo Corp., Japan). Venous blood samples (5 mL) 
were collected from each patient up to 8 h after the initiation of infusion of i.v. 
acetaminophen (detailed in Table 1).  
Blood samples were collected into heparinized tubes and immediately placed on ice, 
with the plasma separated by centrifugation at 3000g for 10 min. Plasma samples were 
stored at −70 °C until analysis. Human plasma concentrations of acetaminophen were 
measured using liquid chromatography–tandem mass spectrometry, performed using a 
Prominence UFLC (Shimadzu Corporation KK, Japan) and an API5000 (AB/MDS 
Sciex, USA). Verapamil hydrochloride was used as an internal standard. 
Chromatographic separation was performed on a 2.1 mm × 75 mm, 2.7 μm Ascentis 
Express C18 column (Sigma-Aldrich Co. LCC, Japan) according to the following 
gradient method (where A is 0.1% formic acid solution and B is acetonitrile)0.00–2.00 
min, 95:5–40:60 A:B v/v; 2.01–4.00 min, 40:60 A:B v/v; 4.00–4.01 min, 40:60–95:5 
A:B v/v; and 4.01–6.50 min, 95:5 A:B v/v. The chromatographic analysis time was 6.5 
min per sample. Calibration curves in human plasma were linear between 0.1 and 50 
μg/mL with 1/x2 as a weighting factor (r ≥ 0.99). The limit of quantitation was 0.1 
μg/mL. The limit of detection was 0.013 μg/mL. 
 Evaluation of existing PK models 
Using the infusion history of acetaminophen and measured plasma acetaminophen 
concentrations obtained in the present study as an evaluation dataset, the predictive 
performances of the three published PK models (detailed in Table 2) were evaluated by 
calculating median absolute prediction error (MDAPE) as a measure of accuracy and 
median prediction error (MDPE) as a measure of bias, as previously described by Varvel 
et al. [7] to compare prediction ability between the models. 
 
PK modeling 
Population compartmental PK parameters were estimated using a mixed-effects 
population approach based on the NONMEM program (version 7.2, ICON 
Development Solutions, Ellicott City, MD, USA). Inter-individual errors for each 
parameter were modeled using a log-normal error model. Residual intra-individual 
errors were modeled using an additive and proportional variance model. The first-order 
conditional estimation method was used for all estimates. Covariates were evaluated, 
including age, sex, height, weight, and creatinine clearance. Continuous covariates other 
than weight were centered at their median value and tested for inclusion using a linear 
relationship. Categorical covariates were tested for inclusion using indicator variables. 
Covariates were selected based on a ‘forward selection’ and then a ‘backward 
elimination’ approach. A respective decrease or increase in the objective function value 
>6.63 (P < 0.01) or 10.83 (P < 0.001) for the inclusion or elimination of covariates was 
considered to be statistically significant. 
 When evaluating the effect of weight as a covariate for each PK parameter, all 
parameter values were standardized to a median value using an allometric model [8] as 
follows:  
Pindividual = Ptypical × (WTindividual/median WT)PWR 
where Pindividual is the parameter of the individual, WTindividual is the weight of the 
individual, and Ptypical is the parameter for an individual with the median weight, which 
in the present study was 70 kg. The PWR exponent was set at 0.75 for clearance 
parameters and 1 for distribution volumes. The quality of the various population models 
constructed by NONMEM was assessed in terms of their ability to predict measured 
plasma concentrations using MDAPE and MDPE. The models were also visually 
assessed by plotting measured/predicted concentrations versus time, and the final model 
was selected. A bootstrapping technique with 1000 replications by PLT tools free 
version 5.4.0 (http://www.pltsoft.com/; last accessed on February 16, 2017) was used to 
compute 95% confidence intervals (CIs) for each parameter in the final model for the 
internal validation of the model and to evaluate parameter uncertainty. Computer 
simulations using the covariate-adjusted population PK model (i.e., the final model) 
were conducted to evaluate the influence of covariates on the transition of plasma 
acetaminophen concentrations with NONMEM program. First, we explored the time 
course of plasma acetaminophen concentration when 1 g of i.v. acetaminophen is 
administered to subjects with various body weights (50, 67, and 85 kg) over 15 min. 
The same simulations were performed using three existing PK models [2, 3, 6] (Table 2) 
with two- or three-compartment model structures. Next, the time courses of plasma 
acetaminophen concentration following three different infusion durations (15, 60, and 
120 min) were simulated using the PK model constructed in the present study. 
 R version 3.2.0 (the R foundation for Statistical Computing) was used for statistical 
analyses and graph generation. 
  
Results 
 
Patients and surgical procedures 
The details of the 12 patients (7 male/5 female) included in this PK study are 
presented in Table 3. The median age was 55 years (range 38–74 years), the median 
height was 163 cm (range 153.4–171.0 cm), and median weight was 63 kg (range 50.0–
85.3 kg). The final two samples could not be collected for one patient in the ‘short’ 
group (patient ID 10) because of occlusion of the sampling port. In total, 185 data points 
(Fig. 1) were obtained. Data points were ignored if the acetaminophen concentrations 
after the start of infusion were below the limit of quantitation; this was the case for three 
data points, all at 1 min after the start of acetaminophen infusion in the ‘short’ group. 
General anesthesia was induced with propofol, remifentanil, and rocuronium and 
maintained with propofol or sevoflurane and remifentanil, with or without fentanyl. 
 
External evaluation 
As illustrated in Fig. 2, the MDPE and MDAPE for the PK model reported by 
Würthwein et al. were within the acceptable range (panel A), where MDPE is between 
−20 and 20% and MDAPE is <30% [9]. In contrast, the MDPE and MDAPE for the PK 
model reported by Wang et al. and Owens et al. were out of the acceptable range (panel 
B and C). 
 
Pharmacokinetic analysis 
The PKs of i.v. acetaminophen were best described using a two-compartment model 
with weight as a covariate (Table 4). The PK model parameter estimates of simple (i.e., 
no covariate effects) and final (significant covariate effects) models are detailed in Table 
4. The weight-scaled model demonstrated better performance than the simple model. 
After incorporating this covariate effect, the objective function significantly improved 
from 369.3 to 355.7. Age, sex, and creatinine clearance were not included as significant 
covariates in the final model. The plots of measured versus predicted value and 
measured divided by predicted value against time (M/P plots) are illustrated in Fig. 3. 
The data points were distributed around the line of identity (Fig. 3a, b). In one of the 
‘long’ group patients, the M/P value was 0.37/3.7 = 0.1 at 5 min after acetaminophen 
infusion (patient ID 4); however, in another patient in the ‘short’ group (patient ID 10), 
the M/P value was 0.44/4.4 = 0.1 at 1 min after acetaminophen infusion, showing 
extremely low M/P values (below the lower limit of the vertical axis in Fig. 3b). The 
MDPE and MDAPE of the final model were −1 and 10%, respectively. The predictive 
performance of the final model was within the acceptable range. The median values of 
the PK parameter estimates and the inter- or intra-variability obtained from the 1000 
bootstrapping resampling were comparable to those of the final model (Table 4). 
 
Simulations 
PK simulations using the current and existing models for patients with three different 
body weights (50, 67, and 85 kg) who received 1 g of i.v. acetaminophen administered 
over 15 min are shown in Figs. 4a–d. In the current model, the predicted peak 
concentrations differed for all three body weights (59.5, 45.9, and 37.1 μg/mL). The 
earliest decline in plasma acetaminophen concentration below the lower limit of the 
therapeutic range (assuming this to be 10 μg/mL [10]) was seen in the heaviest patient, 
with this decline taking 204 min, 158 min, and 116 min after the start of acetaminophen 
infusion in patients weighing 50, 67, and 85 kg, respectively (Fig. 4a). Simulations 
using the PK model reported by Würthwein et al. simulated similar time courses of 
plasma acetaminophen concentrations to those predicted by the current PK model (Fig. 
4b). The PK model reported by Wang et al. predicted largely different peak plasma 
acetaminophen concentrations; however, these were lower than those predicted by the 
other two PK models (Fig. 4c). The PK model reported by Owens et al. predicted 
identical concentration time courses for acetaminophen among patients with different 
body weights (Fig. 4d) because the PK model parameters are not influenced by body 
weight as seen in Table 2. 
 The time courses in the current PK model for plasma acetaminophen concentration 
after the administration of 1 g of i.v. acetaminophen to a patient weighing 67 kg over 
three different durations (15, 60, and 120 min) are depicted in Fig. 5. The maximum 
plasma acetaminophen concentrations reached were 45.9, 25.2, and 19.3 µg/mL, 
respectively, and the concentrations declined <10 µg/ mL at 158, 182, and 214 min after 
the start of acetaminophen infusion. 
Discussion 
 
The novelty of the present study is that the predictive performances of three 
published PK models were evaluated in Japanese patients who underwent surgery and 
received i.v. acetaminophen over durations identical to or longer than that recommended, 
and that a compartmental population PK model of i.v. acetaminophen was constructed 
showing clinically acceptable prediction performance. 
 In our dataset, two data points (for two patients) were observed with M/P values that 
were extremely low, both relating to the first blood sample after administration. One 
assumption of this type of compartmental model is that the drug administered to the 
central compartment is instantaneously mixed. However, this generally accepted 
assumption in pharmacology is not matched by reality and makes it difficult to predict 
the plasma drug concentration in the first minutes after administration, as has been 
reported for propofol [11]. This limitation could have affected the M/P values in our 
results. However, considering that the prediction performance for acetaminophen 
concentration is more important in the elimination phase than the initial distribution 
phase because of the relatively long-acting nature of analgesics, the two low M/P values 
in our results can be clinically overlooked. 
 Three published PK models were evaluated using our acetaminophen dosing and 
concentration records. The PK model reported by Wang et al. showed an unacceptable 
model performance. However, the original dataset of their model was not from 
perioperative patients but from nonJapanese neonates, infants, and children and healthy 
young adult volunteers, and so it is not unreasonable that it did not precisely predict 
acetaminophen concentrations for adult Japanese surgical patients. The performance of 
the model reported by Owens et al. was also unacceptable. Their PK data were obtained 
from New Zealand or Irish patients who underwent major abdominal or breast surgeries. 
The potential differences in their study design compared to that of ours are that they 
performed more invasive procedures, and their PK data included the duration of 
metabolic conversion to acetaminophen glucuronide and subsequent urinary clearance 
in 2–3 days after surgery [12]. These differences may have affected poor predictive 
performance. However, from the above two analyses, it is difficult to determine the 
exact contribution of ethnic differences on the results due to differences in other 
elements of the study designs. In contrast, the model reported by Würthwein et al. 
worked well. Although the original dataset of their model was from non-Japanese 
children and adolescents, the range of weight was not far from that of our evaluation 
dataset, which may be the reason for the good prediction performance of their model. 
Their model did not include age as a covariate, a factor that could have resulted in 
worse performance when the model was extrapolated to adults. However, the PKs in 
patients in our evaluation dataset were not be influenced by age (i.e., the final model did 
not include age as a covariate). Due to these similarities, we concluded that ethnical 
differences did not affect the prediction of the PK model with a compartment structure. 
Factors that influence the PKs of i.v. acetaminophen have been reported in different 
study settings. In studies of perioperative patients, age and sex [13], and age and 
creatinine clearance [3] were found to affect PK parameters. In a PK analysis using a 
pooled historical dataset from past PK studies, including not only perioperative patients 
but also healthy volunteers, intensive care unit patients, and perinatal women, Allegart 
et al. [4] concluded that size, including an allometrically scaled body weight and normal 
fat mass (extension of the concept of predicted normal weight), and age were important 
covariates. In a study of adolescent patients, Würthwein et al. [2] constructed a 
two-compartment PK model and identified weight as a covariate in all PK parameter 
estimates (Table 2), which has a structure and parameter estimate values similar to those 
in the final model constructed in the present study. 
 Simulations to show the impact of weight on the final model were conducted (Fig. 
4a), demonstrating a lower peak and a faster decline in plasma acetaminophen 
concentration with heavier body weight, which is naturally reasonable. In the 
non-compartmental PK analysis of i.v. acetaminophen in young and healthy Japanese 
subjects (29.4 ± 4 years old and 66.1 ± 9 kg; mean and standard deviation), the peak 
plasma acetaminophen concentration was 46.2 ± 5.9 μg/mL [5]. Assuming that this 
acetaminophen concentration is expected for a typical patient, the peak plasma 
acetaminophen concentration (37.1 μg/mL) simulated for a heavier patient may be 
inadequate. In analyzing the drug effects using a compartmental PK model, the 
transition of the drug from the central compartment to the effect site should be taken 
into account as the drug concentration would enhance the drug effect. The cerebrospinal 
fluid (CSF) concentrations can be equated to be the effect site concentrations [14] 
because the time course of acetaminophen concentration in CSF correlates with the 
analgesic and antifebrile effect of the drug [15]. Because acetaminophen is thought to 
penetrate the blood−brain barrier by passive diffusion due to a concentration gradient, 
larger peak concentrations after i.v. administration would contribute to increased 
acetaminophen concentrations in CSF. Thus, as stated before, the lower peak 
concentrations in heavier patients or slow infusion of i.v. acetaminophen may delay the 
onset; these concerns should be examined in the future. The PK model constructed in 
this study and the results of simulations have the potential to provide fundamental 
information regarding the uniform dosing of 1 g acetaminophen to heavy patients and 
the effect of infusion speed for i.v. acetaminophen.  
The present study had some limitations. First, the ranges for age and weight of the 
study population were not wide. In addition, we could not unify the surgical procedure 
received by the patients because of the operating schedule at our institution. Notably, 
most of our patients underwent laparoscopic surgeries, which can reduce liver blood 
flow due to the increase in abdominal air pressure. Clearance of anesthetics with a high 
hepatic extraction like propofol is largely dependent on liver blood [16]. However, 
because the hepatic extraction ratio of acetaminophen is relatively low (0.11–0.37) [17], 
we speculate that the effect of receiving laparoscopic surgeries on the metabolism of 
acetaminophen is restrictive. The extrapolation of the predictions of our PK model to 
other populations including older or heavier patients or patients scheduled to undergo 
different types of procedures including more invasive surgery, should be performed with 
caution. External evaluation to confirm the model predictions for such patients should 
ideally be performed in future.  
In conclusion, the PK model reported by Würthwein et al. worked well when 
evaluated in Japanese patients who underwent surgery under general anesthesia. A 
compartmental population PK model was constructed to simulate i.v. acetaminophen 
concentration. The administration regimen contained slower infusion speeds than 
recommended. Body weight was identified as a covariate in the final model parameter 
estimates. PK simulations with the model demonstrated lower peak plasma 
acetaminophen concentrations in heavier patients and in patients administered a uniform 
dose of 1 g acetaminophen at a slow infusion speed. 
 
Acknowledgments  
I would like to express my deepest gratitude to Dr. Shinju Obara, who helped 
design the study, conduct the study, analyze the data, and write the 
manuscript. 
I also would like to acknowledge Prof. Masahiro Murakawa, who conduct the study and 
approved the final manuscript. 
I would like to acknowledge the expert assistance of Ms. Keiko Sato, MT, who helped 
with the processing of blood samples. 
  
V1 and Vc volume of distribution of the central compartment, WT body weight, V2 V3 and VT volume 
of distribution of the peripheral compartment, VG volume of distribution of acetaminophen glucuronide, 
CL1 central compartment clearance, Vs volume of distribution of acetaminophen sulfate, CL2 and CL3 
peripheral compartment clearances, Vo volume of distribution of acetaminophen cysteine + mercapturate, 
Q intercompartmental clearance, k bodyweight-dependent exponent, k0 value of k at a theoretical 
bodyweight of 0 kg, kmax maximum decrease of k, γ the Hill coefficient that determines the steepness of 
the sigmoidal decline in k, k50 the bodyweight at which a 50% decrease in the maximum decrease of k is 
attained, CLPG formation clearance of acetaminophen glucuronide, CLPS formation clearance of 
Table 1. Sampling schedule for measuring acetaminophen concentrations for each treatment group 
 
 
Group   Sampling schedule 
 
“Short” group  ：0, 1, 2, 4, 8, 12, 15, 17, 20, 25, 30, 60, 120, 240, 360, and 480 min after beginning dosing  
“Medium” group ：0, 5, 10, 15, 25, 35, 60, 65, 75, 80, 90, 120, 240, 360, and 480 min after beginning dosing  
“Long” group  ：0, 5, 15, 25, 35, 60, 90, 120, 125, 130, 140, 150, 180, 240, 360, and 480 min after beginning dosing 
 
 
Table 2. Pharmacokinetic parameter estimates and study backgrounds of the validated models 
   Würthwein et al.[2]  Wang et al. [6]            Owens et al.[3] 
Population Parameters                                                       Population Parameters 
 V1 (L)     13.2*(WT/70)    25.1 * (WT/70)            Vc (L)     13.9 
 V2 (L)     33*(WT/70)     36.1 * (WT/70)            VT (L)     50.9  
 V3 (L)         21.6 * (WT/70)            VG (L)     102 
 CL1 (L/min)   (13.2/60)*(WT/70)0.75    0.293 * (WT/70)k               VS (L)     5.72 
 CL2 (L/min)   (45.7/60)*(WT/70)0.75    1.613 * (WT/70)           VO (L)     17.9 
 CL3 (L/min)              0.023 * (WT/70)           Q (L/h)    77.5 
 k         k0-kmaxWTγ(k50γ+WTγ)      CLPG(L/h)  8.92*(age/median age)−0.00152 
 kmax         0.45                     CLPS (L/h)  0.903 
 k0-kmax        0.75                     CLPO (L/h)  0.533 
 k50         12.2                     CLRG (L/h)  3.81* (CrCL/median CrCL)−0.0129 
 γ         1.4                      CLRS (L/h)  3.13 
CLRO (L/h)  3.51 
CLRP (L/h)  0.137 
Population    Children and adolescents   Preterm and term neonates,  Adults  
        Infants, children and adults 
N of subjects   7      220                      53 
N of sample   37      not applicable             not applicable 
WT range (kg)   39.3－80.0     0.5－94                   54－129 
 
acetaminophen sulfate, CLPO formation clearance of acetaminophen cysteine + mercapturate, CLRG renal 
clearance of acetaminophen glucuronide, CrCL creatinine clearance (ml/ min), CLRS renal clearance of 
acetaminophen sulfate, CLRO renal clearance of acetaminophen cysteine + mercapturate, CLRP renal 
clearance of unchanged/parent acetaminophen 
 
 
ASA American Society of Anesthetists classification, CrCL creatinine clearance (ml/min) 
95% confidence intervals (CI) from 1000 bootstrap replicates were calculated based on the 2.5 percentile 
and 97.5 percentile. Convergence was successful for 956 of the 1000 bootstrap data sets.  
V1, distribution volume of the central compartment; V2, distribution volume of the peripheral 
Table 3.  Patient backgrounds and clinical data from the pharmacokinetics study  
 
ID  Sex     ASA  Age (year)  Height (cm) Weight (kg)  CrCL  Group     Surgical procedures 
1    F  1     40    163   70      112   Long  Laparoscopic myomectomy  
2    M  2     74    170.5  55.2       65   Long  Laparoscopic prostatectomy  
3    F  2     46    161.7  75.4      123   Long  Laparoscopic cholecystectomy  
4    M  2     68    159.6  50.5        57   Long  Laparoscopic prostatectomy  
5    M  1     41    166.3  73.7      102   Medium  Removal of tumor in lower limb  
6    F  1     40    171   57      140   Medium  Laparoscopic ovary removal  
7    F  2     38    165.2  69.4      152   Medium  Laparoscopic myomectomy  
8    M  2     63    163.4  61.5       64   Medium  Laparoscopic prostatectomy  
9    M  2     67    157   50       60   Short  Laparoscopic cholecystectomy  
10   M  2     71    166.5  85.3       66   Short  Laparoscopic cholecystectomy  
11   F  2     42    153.4  57       96   Short  Removal of tumor in lower limb  
12   M  2     70    159.9  63.4       66   Short  Laparoscopic prostatectomy 
Table 4. Pharmacokinetic parameters and performance of the current model  
                 Simple model   Final model 
Population Parameters  Estimates       Estimates    Bootstrap median (95% CI) 
 V1 (L)    10.5        =TVV1 *(WT/70)   
 TVV1                                           11.8    11.7 (8.9-15.3) 
 V2 (L)    27.1        =TVV2 *(WT/70) 
 TVV2            29.8             29.6 (26.5-33.5) 
 CL1 (L/min)   0.21        =TVCL1 * (WT/70)0.75  
 TVCL1           0.22         0.22 (0.21-0.24)   
 CL2 (L/min)   1.1        =TVCL2 * (WT/70)0.75   
 TVCL2                                          1.21   1.20(0.97-1.41) 
Inter-individual variability (%)   
 ωV1    45.6        40.8         42.5 (18.4-59.9) 
 ωV2    21   16.3         16.4 (7.7-28.0) 
 ωCL1    12   8         8.0 (4.0-10.6) 
 ωCL2    23.7   24.5         24.4 (3.5-42.6) 
Intra-individual variability 
 Additive; mcg/ml  0.44        0.45         0.41 (0–1.11) 
 Proportional; %  9.1    8.9         8.7 (4.4-11.1) 
Model performances 
 MDPE (%)   0        −1 
 MDAPE (%)   15        10 
 Objective Function  369.3        355.7 
 
compartment; TVV2, typical value of the distribution volume of the peripheral compartment; WT, weight; 
CL1, central compartment clearance; TVCL1, typical value of central compartment clearance; CL2, 
peripheral compartment clearance; ω, square root of variance of inter-individual variability; MDPE, 
median prediction error; MDAPE, median absolute prediction error. 
 
  
 Acetaminophen concentration versus time on a log scale after 1 g of acetaminophen was 
administered intravenously over 15 min (a n = 4), 60 min (b n = 4), or 120 min (c n = 4) 
 
  
Figure 2 
 
Measured/predicted values versus time in three different existing pharmacokinetic models reported 
by Würthwein et al. [2] (a), Wang et al. [6] (b), and Owens et al. [3]. MDPE median performance 
error, MDAPE median absolute performance error 
 
  
 Measured versus predicted acetaminophen concentrations (a) and measured/ predicted values versus 
time (b) in the final pharmacokinetic model. The black bold lines represent the line of identity. 
MDPE median performance error, MDAPE median absolute performance error 
 
  
   
 Simulations of 1 g of intravenous acetaminophen administered to patients with different body 
weights using the current model (a) and previous models reported by Würthwein et al. [2] (b), Wang 
et al. [6] (c), and Owens et al. [3] (d). Horizontal dot lines are assumed to be the lower limit of the 
therapeutic range (10 μg/mL [10]) 
 Simulations 
of 1 g of intravenous acetaminophen dministered to patients (weight 67 kg) over different durations 
using the current model. The horizontal dotted line indicates the assumed lower limit of the 
therapeutic range (10 μg/mL [10]) 
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